CASI Pharmaceuticals, Inc.
CASI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $13 | $17 | $47 | $39 |
| Short-Term Investments | $3 | $14 | $4 | $10 |
| Receivables | $15 | $10 | $13 | $10 |
| Inventory | $5 | $16 | $6 | $2 |
| Other Curr. Assets | $3 | $3 | $3 | $2 |
| Total Curr. Assets | $40 | $59 | $73 | $62 |
| Property Plant & Equip (Net) | $11 | $12 | $13 | $22 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $2 | $1 | $12 |
| Long-Term Investments | $2 | $2 | $7 | $40 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $2 |
| Total NC Assets | $14 | $16 | $23 | $76 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $54 | $75 | $96 | $138 |
| Liabilities | – | – | – | – |
| Payables | $3 | $4 | $3 | $5 |
| Short-Term Debt | $20 | $1 | $1 | $3 |
| Tax Payable | $0 | $0 | $2 | $1 |
| Deferred Revenue | $2 | $3 | $3 | $0 |
| Other Curr. Liab. | $12 | $9 | $8 | $5 |
| Total Curr. Liab. | $36 | $17 | $17 | $13 |
| LT Debt | $3 | $21 | $0 | $1 |
| Deferred Rev, NC | $0 | $0 | $0 | $3 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $13 | $14 | $12 | $13 |
| Total NC Liab. | $15 | $34 | $12 | $17 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $4 | $2 | $1 | $2 |
| Total Liabilities | $52 | $51 | $29 | $30 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $1 |
| Retained Earnings | -$700 | -$661 | -$637 | -$606 |
| AOCI | -$2 | -$1 | -$1 | $2 |
| Other Equity | $704 | $686 | $682 | $687 |
| Total Equity | $2 | $24 | $45 | $85 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $22 | $23 |
| Total Liab. & Tot. Equity | $54 | $75 | $96 | $138 |
| Net Debt | $9 | $4 | -$46 | -$34 |